CN115211517A - Solid beverage with uric acid reducing effect and preparation method thereof - Google Patents
Solid beverage with uric acid reducing effect and preparation method thereof Download PDFInfo
- Publication number
- CN115211517A CN115211517A CN202210935322.XA CN202210935322A CN115211517A CN 115211517 A CN115211517 A CN 115211517A CN 202210935322 A CN202210935322 A CN 202210935322A CN 115211517 A CN115211517 A CN 115211517A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- powder
- extract
- parts
- uric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 50
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229940116269 uric acid Drugs 0.000 title claims abstract description 44
- 230000001603 reducing effect Effects 0.000 title claims abstract description 28
- 235000013361 beverage Nutrition 0.000 title claims abstract description 18
- 239000007787 solid Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 87
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 49
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 24
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 24
- 229940046009 vitamin E Drugs 0.000 claims abstract description 24
- 239000011709 vitamin E Substances 0.000 claims abstract description 24
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 20
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 20
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 20
- 229960002477 riboflavin Drugs 0.000 claims abstract description 20
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 20
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 20
- 238000002156 mixing Methods 0.000 claims abstract description 19
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 19
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 19
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 19
- 239000004376 Sucralose Substances 0.000 claims abstract description 18
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 18
- 239000003094 microcapsule Substances 0.000 claims abstract description 18
- 235000019408 sucralose Nutrition 0.000 claims abstract description 18
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 18
- 229960003495 thiamine Drugs 0.000 claims abstract description 18
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 18
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 18
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 18
- 241000219226 Acer truncatum Species 0.000 claims abstract description 17
- 235000005805 Prunus cerasus Nutrition 0.000 claims abstract description 17
- 229930006000 Sucrose Natural products 0.000 claims abstract description 17
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 17
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 17
- 229930195729 fatty acid Natural products 0.000 claims abstract description 17
- 239000000194 fatty acid Substances 0.000 claims abstract description 17
- 239000005720 sucrose Substances 0.000 claims abstract description 17
- -1 sucrose fatty acid ester Chemical class 0.000 claims abstract description 17
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 17
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 17
- 240000007087 Apium graveolens Species 0.000 claims abstract description 16
- 235000009226 Prunus puddum Nutrition 0.000 claims abstract description 16
- 239000001387 apium graveolens Substances 0.000 claims abstract description 16
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 16
- 241000251468 Actinopterygii Species 0.000 claims abstract description 15
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims abstract description 14
- 235000010591 Appio Nutrition 0.000 claims abstract description 14
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 14
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 14
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 14
- 235000019198 oils Nutrition 0.000 claims abstract description 13
- 240000008042 Zea mays Species 0.000 claims abstract description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 12
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 12
- 229940055416 blueberry extract Drugs 0.000 claims abstract description 12
- 235000019216 blueberry extract Nutrition 0.000 claims abstract description 12
- 235000005822 corn Nutrition 0.000 claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 12
- 229940094952 green tea extract Drugs 0.000 claims abstract description 12
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 12
- 239000004386 Erythritol Substances 0.000 claims abstract description 11
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940009714 erythritol Drugs 0.000 claims abstract description 11
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 11
- 235000019414 erythritol Nutrition 0.000 claims abstract description 11
- 238000005303 weighing Methods 0.000 claims abstract description 10
- 244000207449 Prunus puddum Species 0.000 claims abstract 4
- 239000000463 material Substances 0.000 claims description 29
- 229930003270 Vitamin B Natural products 0.000 claims description 13
- 235000019156 vitamin B Nutrition 0.000 claims description 13
- 239000011720 vitamin B Substances 0.000 claims description 13
- 238000011068 loading method Methods 0.000 claims description 11
- 239000000686 essence Substances 0.000 claims description 7
- 230000033001 locomotion Effects 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 16
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract description 14
- 201000005569 Gout Diseases 0.000 abstract description 13
- 230000009466 transformation Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 210000002700 urine Anatomy 0.000 abstract description 2
- 240000002878 Prunus cerasus Species 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 201000001431 Hyperuricemia Diseases 0.000 description 12
- 108010093894 Xanthine oxidase Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 102100033220 Xanthine oxidase Human genes 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 201000010000 Agranulocytosis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 3
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 3
- 229960002529 benzbromarone Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 3
- 229960005101 febuxostat Drugs 0.000 description 3
- 235000009569 green tea Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 3
- 229960003081 probenecid Drugs 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 235000002764 Apium graveolens Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010018687 Granulocytopenia Diseases 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 240000000851 Vaccinium corymbosum Species 0.000 description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000021014 blueberries Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- GWGLGTKSTGSWGQ-UPHRSURJSA-N (z)-4-(carbamoylamino)-4-oxobut-2-enoic acid Chemical compound NC(=O)NC(=O)\C=C/C(O)=O GWGLGTKSTGSWGQ-UPHRSURJSA-N 0.000 description 1
- URQMEZRQHLCJKR-UHFFFAOYSA-N 3-Methyl-5-propyl-2-cyclohexen-1-one Chemical compound CCCC1CC(C)=CC(=O)C1 URQMEZRQHLCJKR-UHFFFAOYSA-N 0.000 description 1
- 241001143500 Aceraceae Species 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 235000009836 Prunus pissardii Nutrition 0.000 description 1
- 244000277586 Prunus pissardii Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000134968 Sapindales Species 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000012511 Vaccinium Nutrition 0.000 description 1
- 241000736767 Vaccinium Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001453 anthocyanidins Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 239000001556 apium graveolens l. seed extract Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940116732 celery seed extract Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 125000005506 phthalide group Chemical group 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical group 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
The invention discloses a solid beverage with uric acid reducing effect and a preparation method thereof, and the solid beverage is prepared by weighing: erythritol, diglyceride oil powder, celery seed powder, celery juice powder, lophatherum gracile extract, corn stigma extract, blueberry extract, green tea extract, marine fish oligopeptide, sour cherry fruit powder, acer truncatum seed oil microcapsule powder, edible essence, sucrose fatty acid ester, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12 and sucralose; pre-mixing and total mixing; and finally, subpackaging. The invention can inhibit the absorption and transformation of purine in the body, promote purine to be discharged out of the body along with urine, and has obvious effects of reducing uric acid and preventing gout.
Description
Technical Field
The invention belongs to the field of health-care food, and particularly relates to a solid beverage with a uric acid reducing effect and a preparation method thereof.
Background
Hyperuricemia (HUA) refers to a condition of two fasting blood uric acid levels higher than 420. Mu. Mol/L in men and higher than 360. Mu. Mol/L in women under normal purine diet, which is called hyperuricemia. With the improvement of living standard and the change of eating habit of people, the incidence of hyperuricemia in China is on the trend of increasing year by year and the trend of younger year. Uric acid is a terminal metabolite of purine compounds metabolism in humans, and hyperuricemia is a metabolic disorder syndrome caused by purine metabolic disorders. When the blood uric acid exceeds the saturation degree of the blood uric acid in blood or tissue fluid, sodium urate crystals can be formed and deposited on the local joints, so that organ and tissue diseases of a human body are caused, gout is caused, and serious complications are caused, including gouty arthritis, gouty kidney disease, gouty kidney stone, gouty heart disease, gouty hypertension and the like.
In clinical treatment of hyperuricemia, western medicines mainly use analgesic and anti-inflammatory medicines to temporarily relieve pain. Such as febuxostat, allopurinol, colchicine, benzbromarone, probenecid and the like. In the final step of purine metabolism, hypoxanthine is generated into xanthine under the action of Xanthine Oxidoreductase (XOR), and then uric acid is further generated, and febuxostat and allopurinol are inhibitors of the xanthine oxidoreductase, and the two drugs are highly selectively acted on the oxidase to reduce the synthesis of uric acid in vivo and reduce the concentration of uric acid, so that gout is effectively treated. Colchicine has analgesic effect by reducing leukocyte activity and phagocytosis and reducing lactic acid formation to reduce uric acid crystal deposition and relieve inflammatory reaction. Benzbromarone and probenecid reduce the concentration of urate in blood by inhibiting the active reabsorption of urate by renal tubules, increasing the excretion of urate, alleviating or preventing the formation of urate nodules, reducing the injury of alleviation, and promoting the dissolution of urate that has formed. Although the medicines have better curative effect on gout, certain toxic and side effects are shown in clinic. Among them, the adverse reactions of febuxostat include abnormal liver function, diarrhea, headache, joint-related symptoms and symptoms, and musculoskeletal connective tissue symptoms. The allopurinol has the adverse reactions of common skin rash, diarrhea and abdominal pain, low fever, temporary transaminase rise or granulocytopenia and the like. Colchicine is extremely toxic, and is commonly seen in nausea, vomiting, diarrhea, abdominal pain, gastrointestinal reaction, hematuria and oliguria, has direct inhibition effect on bone marrow, causes agranulocytosis, aplastic anemia and the like. Benzbromarone can cause granulocytopenia. Probenecid is common in adverse reactions such as gastrointestinal reaction, rash, fever and the like, and the long-term use of the drugs brings great pain to patients, threatens health and influences life quality.
The traditional Chinese medicine causes of gout: 1. yang exuberance of the body and accumulated toxicity in zang-fu organs. Heat accumulation in the zang-fu organs is a prerequisite for forming toxic pathogen to attack the bone joint, and long-term heat accumulation, heat stagnation as toxin is the root cause of gout. 2. Damp-heat and turbid-toxin remained in the joints. Dampness-heat and turbidity-toxin, which is rooted in the spleen and stomach, stagnates meridians, blocks meridians and collaterals, flows into joints, and if the healthy qi is deficient and pathogenic factors lingers, the dampness-toxin is not removed, it flows through the meridians and attaches to the bone joints to form the phlegm-stone which is hard like the stone. Therefore, damp-heat and turbid-toxin are the main causes of the formation of tophus. 3. Spleen deficiency is the principal and dampness-turbidity is the secondary. The deficient spleen and stomach, together with improper diet, can impair the spleen and stomach, cause disorders of transportation and transformation, induce damp turbidity, and cause diseases of the body by injecting into the skin, flesh and joints and leaving viscera inside. 4. Invasion of exogenous pathogenic factors can lead to retention of exogenous pathogenic factors. Muscle joints cause unsmooth qi and blood, blockage of channels and collaterals, and pain due to blockage, which can cause deficiency of qi and blood, blood heat causing stasis, and obstruction of channels and collaterals, and cause arthrocele, deformity and stiffness. The Chinese medicine needs to classify symptoms for treating hyperuricemia and gout, and cannot achieve universality.
Hyperuricemia and gout are a continuous, chronic pathophysiological process, so that management of hyperuricemia and gout should also be a continuous process, and long-term and even lifetime condition monitoring and management is required. The functional food capable of reducing uric acid is reasonably selected, the generation of uric acid of a human body is controlled by daily drinking, the blood uric acid is reduced, the occurrence of hyperuricemia and gout is reduced, and the health care tea is safe and has no toxic or side effect.
Disclosure of Invention
The invention aims to provide a solid beverage with the efficacy of reducing uric acid and a preparation method thereof, which can solve the problems in the background art.
The invention relates to a solid beverage with uric acid reducing effect, which is characterized in that: the raw materials and the parts by weight are as follows: 20-50 parts of erythritol, 10-50 parts of diglyceride oil powder, 10-50 parts of celery seed powder, 5-50 parts of celery juice powder, 1-20 parts of lophatherum gracile extract, 1-20 parts of corn stigma extract, 1-20 parts of blueberry extract, 0.1-2 parts of green tea extract, 1-10 parts of marine fish oligopeptide, 0.01-1 part of sour cherry fruit powder, 0.001-1 part of acer truncatum seed oil microcapsule powder, 0.001-1 part of edible essence, 0.001-1 part of sucrose fatty acid ester, 0.01-1 part of vitamin E, 0.001-1 part of vitamin B1, 0.001-1 part of vitamin B2, 0.001-1 part of vitamin B6, 0.000000001-1 part of vitamin B and 0.001-1 part of sucralose.
The diglyceride oil powder comprises at least one of diglyceride microcapsule powder, diglyceride embedded powder and diglyceride oil powder. The diglyceride powder can reduce the Xanthine Oxidase (XOD) activity of serum and liver, and can reduce the expression level of renal cortical uric acid Transporter1 (URAT 1), thereby inhibiting xanthine generation and further reducing uric acid formation.
The celery seed powder comprises at least one of celery seed powder and celery seed extract. The celery seed is seed of Apium graveolens of Umbelliferae, contains abundant vitamins and volatile aromatic components, contains phthalides with obvious uric acid reducing and pain relieving effects, and is an active ingredient for resisting gout.
The celery juice powder comprises at least one of celery powder, celery juice powder and celery juice extract. Celery is Apium graveolens belonging to Umbelliferae, and contains apigenin which can reduce Serum Uric Acid (SUA) level by inhibiting in vivo Adenosine Dehydrogenase (ADA) activity, and further reduce Uric Acid formation
The sour cherry powder comprises at least one of sour cherry powder, sour cherry juice powder and sour cherry extract. Sour cherry is also called prunus cerasus, and is a fruit of prunus cerasifera which is native to europe. It is rich in anthocyanidin, and has effects of inhibiting Xanthine Oxidase (XOD) and reducing uric acid formation.
The acer truncatum seed oil powder comprises at least one of acer truncatum seed oil powder, acer truncatum seed oil embedding powder and acer truncatum seed oil microcapsule powder. Acer truncatum seed oil is prepared from seed of Acer truncatum Bunge of Aceraceae of Sapindales, and is a new resource food with effects of regulating immunity, increasing NK cell activity, and improving organism cellular immunity and humoral immunity.
The lophatherum gracile extract, the corn stigma extract, the blueberry extract and the green tea extract are dried substances obtained by a water extraction process. Lophatherum gracile is the dried stem and leaf of Lophatherum gracile of Gramineae. Being sweet, bland and cold in nature and good in property, it enters heart, small intestine and bladder meridians, and can clear heart fire, relieve restlessness, induce diuresis and treat stranguria. The stigma Maydis is flower column and flower head of Gramineae plant semen Maydis. Sweet taste and slightly warm nature. Enter bladder, liver and gallbladder meridians. It has the functions of inducing diuresis to reduce edema, clearing away liver heat and promoting bile flow. The blueberry is fruit of blueberries of Vaccinium of Ericaceae, contains abundant anthocyanin, and has effects of inhibiting Xanthine Oxidase (XOD) and reducing uric acid formation. The green tea has good antioxidant and tranquilizing effects, and can relieve fatigue. Green tea is rich in vitamin C and flavonoids. In addition, green tea powder has promoting effects on relieving constipation, reducing weight, beautifying body and reducing weight.
The vitamin E comprises at least one of vitamin E powder, coating vitamin E powder, vitamin E microcapsule powder and vitamin E embedding powder. Vitamin E, also known as tocopherol or gestagen, is one of the most important antioxidants. Vitamin E can protect the stability of cell membrane by interrupting the chain reaction of free radicals, regulate the normal secretion of hormone in vivo, prevent LDL cholesterol from being oxidized, and has synergistic effect with other vitamins.
The vitamin B1, the vitamin B2, the vitamin B6 and the vitamin B12 comprise at least one of vitamin B1 powder, vitamin B2 powder, vitamin B6 powder, vitamin B12 powder, vitamin B1 embedding powder, vitamin B2 embedding powder, vitamin B6 embedding powder, vitamin B12 powder, vitamin B1 microcapsule powder, vitamin B2 microcapsule powder, vitamin B6 microcapsule powder and vitamin B12 microcapsule powder. Vitamin B1, vitamin B2, vitamin B6 and vitamin B12 belong to the vitamin B group and are necessary rings for metabolism in the body, and the components cooperate to help the metabolism of saccharides, fat and protein to release energy.
The marine fish oligopeptide is a dried product obtained by carrying out enzymolysis on marine fish. The marine fish oligopeptide is called as marine fish collagen peptide, and researches show that when a certain amount of marine and oligopeptide acts on a human body, the quantity of HPRT enzyme and LDH can be increased, so that purine substances can be effectively prevented from being retained in the body, the content of uric acid is reduced, and uric acid crystals at joints are dissolved.
A preparation method of a solid beverage with the efficacy of reducing uric acid is characterized by comprising the following steps:
(1) Weighing: erythritol, diglyceride oil powder, celery seed powder, celery juice powder, lophatherum gracile extract, corn stigma extract, blueberry extract, green tea extract, marine fish oligopeptide, sour cherry fruit powder, acer truncatum seed oil microcapsule powder, edible essence, sucrose fatty acid ester, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12 and sucralose can be accurately weighed according to required materials; the specific weighing value refers to the value range of claim 1;
(2) Premixing: premixing edible essence, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, sucralose and sucrose fatty acid ester by a V-shaped mixer for 30-40 minutes at normal temperature, wherein the loading amount of the edible essence is not more than 50% of the volume of the mixer; carrying out premixing;
(3) Total mixing: putting the rest materials and the premixed materials into a three-dimensional motion mixer, wherein the loading amount is not more than 75 percent of the volume of the mixer, and mixing for 30-40 minutes at normal temperature;
(4) Subpackaging: and packaging the total mixed materials into products of 5-15 g/bag.
The beneficial effects of the invention are: unsaturated lipids, peptides, vitamins, new resource food and food raw materials which are homologous in medicine and food are matched with each other to regulate functions of each system of a human body, so that functions of internal organs of the human body are normal, damaged cells are repaired, immunity is improved, the effects of inducing diuresis and clearing damp are enhanced, heat and toxic materials are removed, dampness is removed, diuresis is induced, meridians are dredged to relieve pain, yin and yang are balanced, the excretion function of the body is improved, absorption and transformation of purine in the body are inhibited, purine is promoted to be discharged out of the body along with urine, the effects of reducing uric acid and preventing gout are obvious, and other uncomfortable symptoms are eliminated.
Detailed Description
The present invention will be described in detail with reference to examples.
In the case of the example 1, the following examples are given,
a preparation method of a solid beverage with uric acid reducing effect comprises the following steps:
(1) Weighing: the raw materials can be accurately weighed according to the required materials, and the raw materials comprise, by weight, 20 parts of erythritol, 10 parts of diglyceride oil powder, 15 parts of celery seed powder, 20 parts of celery juice powder, 1 part of lophatherum gracile extract, 1 part of corn stigma extract, 1 part of blueberry extract, 0.1 part of green tea extract, 1 part of marine fish oligopeptide, 0.01 part of sour cherry powder, 0.001 part of acer truncatum seed oil microcapsule powder, 0.001 part of edible essence, 0.001 part of sucrose fatty acid ester, 0.01 part of vitamin E, 0.001 part of vitamin B2, 0.001 part of vitamin B6, 0.00001 part of vitamin B12 and 0.001 part of sucralose;
(2) Pre-mixing: premixing edible essence, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, sucralose and sucrose fatty acid ester by adopting a V-shaped mixer, wherein the charging amount of the V-shaped mixer is 50 percent of the volume of the mixer, and premixing for 30 minutes at normal temperature;
(3) Total mixing: putting the rest materials and the premixed materials into a three-dimensional motion mixer, wherein the loading amount is 75 percent of the volume of the mixer, and mixing for 30 minutes at normal temperature;
(4) Subpackaging: and packaging the total mixed materials into products of 5 g/bag.
In the case of the example 2, the following examples are given,
a preparation method of a solid beverage with the efficacy of reducing uric acid comprises the following steps:
(1) Weighing: the feed additive can be accurately weighed according to the required materials, and comprises, by weight, 50 parts of erythritol, 50 parts of diglyceride oil powder, 50 parts of celery seed powder, 50 parts of celery juice powder, 20 parts of lophatherum gracile extract, 20 parts of corn stigma extract, 20 parts of blueberry extract, 2 parts of green tea extract, 10 parts of marine fish oligopeptide, 1 part of sour cherry fruit powder, 1 part of acer truncatum seed oil microcapsule powder, 1 part of edible essence, 1 part of sucrose fatty acid ester, 1 part of vitamin E, 1 part of vitamin B2, 6 parts of vitamin B, 12 parts of vitamin B and 1 part of sucralose;
(2) Pre-mixing: premixing edible essence, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, sucralose and sucrose fatty acid ester by adopting a V-shaped mixer, wherein the loading amount of the V-shaped mixer is 49 percent of the volume of the mixer, and premixing for 36 minutes at normal temperature;
(3) Total mixing: putting the rest materials and the premixed materials into a three-dimensional motion mixer, wherein the loading amount of the premixed materials is 70% of the volume of the mixer, and mixing for 38 minutes at normal temperature;
(4) Subpackaging: and packaging the total mixed materials into products of 10 g/bag.
In the case of the embodiment 3, the following examples,
a preparation method of a solid beverage with uric acid reducing effect comprises the following steps:
(1) Weighing: the feed additive can be accurately weighed according to the required materials, and comprises, by weight, 30 parts of erythritol, 30 parts of diglyceride oil powder, 10 parts of celery seed powder, 5 parts of celery juice powder, 10 parts of lophatherum gracile extract, 10 parts of corn stigma extract, 10 parts of blueberry extract, 1 part of green tea extract, 5 parts of marine fish oligopeptide, 0.5 part of sour cherry fruit powder, 0.5 part of acer truncatum seed oil microcapsule powder, 0.5 part of edible essence, 0.5 part of sucrose fatty acid ester, 0.5 part of vitamin E, 0.5 part of vitamin B1, 0.5 part of vitamin B2, 0.4 part of vitamin B6, 0.00005 part of vitamin B12 and 0.5 part of sucralose;
(2) Premixing: premixing edible essence, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, sucralose and sucrose fatty acid ester by adopting a V-shaped mixer, wherein the charging amount of the V-shaped mixer is 48 percent of the volume of the mixer, and premixing for 40 minutes at normal temperature;
(3) Total mixing: putting the rest materials and the premixed materials into a three-dimensional motion mixer, wherein the loading amount is 72 percent of the volume of the mixer, and mixing for 40 minutes at normal temperature;
(4) Subpackaging: and packaging the mixed materials into 9 g/bag of products.
In the case of the example 4, the following examples are given,
a preparation method of a solid beverage with the efficacy of reducing uric acid comprises the following steps:
(1) Weighing: the health-care food can be accurately weighed according to the required materials, and comprises, by weight, 40 parts of erythritol, 22 parts of diglyceride oil powder, 26 parts of celery seed powder, 35 parts of celery juice powder, 12 parts of lophatherum gracile extract, 13 parts of corn stigma extract, 14 parts of blueberry extract, 0.8 part of green tea extract, 8 parts of marine fish oligopeptide, 0.18 part of sour cherry fruit powder, 0.29 part of acer truncatum seed oil micro-capsule powder, 0.008 part of edible essence, 0.009 part of sucrose fatty acid ester, 0.1 part of vitamin E, 0.2 part of vitamin B, 0.08 part of vitamin B, 0.07 part of vitamin B, 0.0007 part of vitamin B and 0.09 part of sucralose;
(2) Premixing: premixing edible essence, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, sucralose and sucrose fatty acid ester by adopting a V-shaped mixer, wherein the loading amount of the V-shaped mixer is 50 percent of the volume of the mixer, and premixing for 32 minutes at normal temperature;
(3) Total mixing: putting the rest materials and the premixed materials into a three-dimensional motion mixer, wherein the loading amount is 73 percent of the volume of the mixer, and mixing for 37 minutes at normal temperature;
(4) Subpackaging: and packaging the mixed materials into 8 g/bag of products.
In the case of the example 5, the following examples were conducted,
a preparation method of a solid beverage with uric acid reducing effect comprises the following steps:
(1) Weighing: the raw materials can be accurately weighed according to the required parts by weight, 35 parts of erythritol, 32 parts of diglyceride oil powder, 47 parts of celery seed powder, 40 parts of celery juice powder, 8 parts of lophatherum gracile extract, 7 parts of corn stigma extract, 5 parts of blueberry extract, 1.8 parts of green tea extract, 4 parts of marine fish oligopeptide, 0.98 part of sour cherry fruit powder, 0.05 part of acer truncatum seed oil microcapsule powder, 0.08 part of edible essence, 0.06 part of sucrose fatty acid ester, 0.04 part of vitamin E, 0.35 part of vitamin B, 0.57 part of vitamin B, 0.39 part of vitamin B, 0.00008 part of vitamin B and 0.22 part of sucralose;
(2) Premixing: premixing edible essence, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, sucralose and sucrose fatty acid ester by adopting a V-shaped mixer, wherein the charging amount of the V-shaped mixer is 49 percent of the volume of the mixer, and premixing for 37 minutes at normal temperature;
(3) Total mixing: putting the rest materials and the premixed materials into a three-dimensional motion mixer, wherein the loading amount is 74 percent of the volume of the mixer, and mixing for 36 minutes at normal temperature;
(4) Subpackaging: and (4) packaging the mixed materials into products of 15 g/bag.
The scheme of the invention is used, and the person with higher uric acid is selected for practical use, and the recording and the effect evaluation are carried out as follows:
clinically, the normal values of male uric acid: 149-416 mol/L, if exceeding the index, belonging to hyperuricemia. 20 male hyperuricemia volunteers were randomly collected, and the blood uric acid was above 420 mol/L. The uric acid reducing solid beverage in the embodiment 1 of the invention is orally taken every day, one packet is taken every time, and the solid beverage is taken twice a day.
Criteria for therapeutic effect
The composition is administered continuously for 20 days, and the blood uric acid is reduced by more than 100mol/L after administration compared with before administration.
The composition is administered continuously for 20 days, and the blood uric acid is reduced by less than 100mol/L after administration.
The composition is administered continuously for 20 days, and the blood uric acid is reduced by less than 20mol/L after administration
Therapeutic efficacy analysis and statistics
From the results, the scheme of the invention can effectively and rapidly reduce the uric acid level, and after eating for 20 days, the effective cases account for 60%, the effective cases account for 35%, the ineffective cases account for 5%, and the total effective rate for reducing uric acid is 95%.
The tests prove that the solid beverage and the preparation method thereof provided by the invention are more scientific, reasonable and healthy and have good using effect. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features related to the embodiments of the present invention described above may be combined with each other as long as they do not conflict with each other. In addition, the above embodiments are only some embodiments of the present invention, not all embodiments, and all other embodiments obtained by those skilled in the art based on the embodiments of the present invention without any creative work belong to the protection scope of the present invention.
Claims (2)
1. A solid beverage with uric acid reducing effect is characterized in that: the raw materials and the parts by weight are as follows:
20-50 parts of erythritol, 10-50 parts of diglyceride oil powder, 10-50 parts of celery seed powder, 5-50 parts of celery juice powder, 1-20 parts of lophatherum gracile extract, 1-20 parts of corn stigma extract, 1-20 parts of blueberry extract, 0.1-2 parts of green tea extract, 1-10 parts of marine fish oligopeptide, 0.01-1 part of sour cherry fruit powder, 0.001-1 part of acer truncatum seed oil microcapsule powder, 0.001-1 part of edible essence, 0.001-1 part of sucrose fatty acid ester, 0.01-1 part of vitamin E, 0.001-1 part of vitamin B1, 0.001-1 part of vitamin B2, 0.001-1 part of vitamin B6, 0.000000001-1 part of vitamin B and 0.001-1 part of sucralose.
2. A preparation method of a solid beverage with uric acid reducing effect is characterized by comprising the following steps:
(1) Weighing: erythritol, diglyceride oil powder, celery seed powder, celery juice powder, lophatherum gracile extract, corn stigma extract, blueberry extract, green tea extract, marine fish oligopeptide, sour cherry fruit powder, acer truncatum seed oil microcapsule powder, edible essence, sucrose fatty acid ester, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12 and sucralose, wherein the erythritol, the diglyceride oil powder, the celery seed powder, the lophatherum gracile extract, the corn stigma extract, the blueberry extract, the green tea extract, the marine fish oligopeptide, the sour cherry fruit powder, the acer truncatum seed oil microcapsule powder and the sucralose are accurately weighed according to required materials; the specific weighing value refers to the value range of claim 1;
(2) Pre-mixing: premixing edible essence, vitamin E, vitamin B1, vitamin B2, vitamin B6, vitamin B12, sucralose and sucrose fatty acid ester by a V-shaped mixer at normal temperature for 30-40 minutes, wherein the loading amount of the edible essence is not more than 50% of the volume of the mixer;
(3) Total mixing: putting the rest materials and the premixed materials into a three-dimensional motion mixer, wherein the loading amount is not more than 75 percent of the volume of the mixer, and mixing for 30-40 minutes at normal temperature;
(4) Subpackaging: and packaging the total mixed materials into products of 5-15 g/bag.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210935322.XA CN115211517A (en) | 2022-08-05 | 2022-08-05 | Solid beverage with uric acid reducing effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210935322.XA CN115211517A (en) | 2022-08-05 | 2022-08-05 | Solid beverage with uric acid reducing effect and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115211517A true CN115211517A (en) | 2022-10-21 |
Family
ID=83615425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210935322.XA Pending CN115211517A (en) | 2022-08-05 | 2022-08-05 | Solid beverage with uric acid reducing effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115211517A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116369530A (en) * | 2023-05-08 | 2023-07-04 | 海南华研胶原科技股份有限公司 | Uric acid-reducing collagen peptide oral liquid rich in vitamin C and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108065166A (en) * | 2017-12-21 | 2018-05-25 | 深圳万和制药有限公司 | Solid beverage composition with anti-trioxypurine effect |
| CN108391774A (en) * | 2018-05-25 | 2018-08-14 | 张瑞雪 | A kind of drinks of antigout and preparation method thereof |
| CN109452521A (en) * | 2018-12-26 | 2019-03-12 | 广东养慕特殊医用食品有限公司 | A kind of anti-trioxypurine peptide solid beverage, Preparation method and use |
| CN109758571A (en) * | 2019-03-27 | 2019-05-17 | 长春健康未来医药科技有限公司 | A kind of promotion uric acid metabolism improves gout, the composition of Saving cortilage and preparation method thereof |
| CN113350328A (en) * | 2020-09-27 | 2021-09-07 | 广州永华特医营养科技有限公司 | New application of diglyceride and composition thereof |
-
2022
- 2022-08-05 CN CN202210935322.XA patent/CN115211517A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108065166A (en) * | 2017-12-21 | 2018-05-25 | 深圳万和制药有限公司 | Solid beverage composition with anti-trioxypurine effect |
| CN108391774A (en) * | 2018-05-25 | 2018-08-14 | 张瑞雪 | A kind of drinks of antigout and preparation method thereof |
| CN109452521A (en) * | 2018-12-26 | 2019-03-12 | 广东养慕特殊医用食品有限公司 | A kind of anti-trioxypurine peptide solid beverage, Preparation method and use |
| CN109758571A (en) * | 2019-03-27 | 2019-05-17 | 长春健康未来医药科技有限公司 | A kind of promotion uric acid metabolism improves gout, the composition of Saving cortilage and preparation method thereof |
| CN113350328A (en) * | 2020-09-27 | 2021-09-07 | 广州永华特医营养科技有限公司 | New application of diglyceride and composition thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116369530A (en) * | 2023-05-08 | 2023-07-04 | 海南华研胶原科技股份有限公司 | Uric acid-reducing collagen peptide oral liquid rich in vitamin C and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109452521B (en) | Auxiliary uric acid peptide reducing solid beverage, preparation method and application | |
| US9149500B2 (en) | Method and process for relieving or preventing symptoms | |
| EP3626249A2 (en) | Traditional chinese medicine healthcare preparation for fat elimination and weight reduction | |
| CN109758571A (en) | A kind of promotion uric acid metabolism improves gout, the composition of Saving cortilage and preparation method thereof | |
| JP2002512197A (en) | Rose seed formulation as a natural anti-inflammatory drug to alleviate and alleviate symptoms associated with inflammation and arthritis | |
| CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
| CN108618126A (en) | A kind of Chinese medicine compound prescription weight-reducing special diet food and preparation method thereof | |
| KR101579845B1 (en) | Composition that comprising fenugreek extract or compound including fenugreek extract for preventing and improving the andropause or male menopause symptom which involves lethargy, hypotrophy, muscle weakness, increasing visceral fat, tiredness and stress, by increasing testosterone level, endurance, muscle mass and decreasing visceral fat and improving blood lipid composition, number of sperm and activation of sperm | |
| CN108175024A (en) | A kind of sunflower flower powder solid beverage and preparation method | |
| CN115211517A (en) | Solid beverage with uric acid reducing effect and preparation method thereof | |
| CN101147527B (en) | Feed capable of leading duck egg to have softening blood vessel and reducing blood pressure function and preparation method | |
| KR100492470B1 (en) | Composition for treating and preventing gout | |
| KR20080090808A (en) | Composition of healthy food for a skin | |
| CN110227095A (en) | A kind of anti-trioxypurine composition and preparation method thereof | |
| RU2205655C1 (en) | Agent for prophylaxis and treatment of urolithiasis disease | |
| CN101904501A (en) | Functional food for relieving fatigue and preparation method thereof | |
| CN106822684A (en) | Prevent and treat Chinese medicine composition, medicine of hyperuricemia and its preparation method and application | |
| KR0137897B1 (en) | Health food containing leaf of eucommia ulmoides oliver | |
| CN112439030A (en) | Medicine for quickly reducing uric acid | |
| KR100834487B1 (en) | Beverage or drug containing bamboo extract as main ingredient | |
| KR102506493B1 (en) | Composition for preventing or treating edema comprising Prasiola japonica extract or fraction thereof as active ingredient | |
| CN115177732B (en) | Composition for assisting in preventing and relieving gout | |
| EP3960194B1 (en) | Composition for reducing the symptoms of nocturia | |
| KR101695299B1 (en) | Composition for preventing or treating obesity or hyperlipidemia containing Piper longum extract, soy extract containing isoflavon and L-carnitin | |
| Govindan et al. | Impact of Vitamins and Minerals Enriched Flora in the Management of Calciphytoliths: A Special Focus on Vitamin E |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |